REstoration of VItamin D in Pulmonary Arterial Hypertension
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
Background. Pulmonary arterial hypertension (PAH) is a heterogeneous pathophysiological condition characterized by progressive pulmonary vascular narrowing that ultimately results in right-sided heart failure and eventually death or lung transplantation. The effectiveness of current pharmacological treatments is suboptimal and a large proportion of patients still had events or died despite receiving combination therapy. Vitamin D deficiency has been found to be much more frequent in PAH patients than in the general population or even compared to patients with other severe cardiovascular diseases. Moreover, vitamin D deficiency has a negative prognostic impact in PAH. Animal studies support that vitamin D deficiency worsens PAH.
Hypothesis. In patients with PAH and vitamin D deficiency, restoration of vitamin D status with calcifediol improves their symptomatology and prognosis.
Design: Multicenter clinical trial with the participation of 9 hospitals, placebo-controlled, randomized (1:1 ratio), in two parallel groups (without crossover), triple blind, and add-on on existing treatments (add-on). It will include at least 102 subjects (51 in the calcifediol group and 51 in the placebo group) followed for 24 weeks of treatment.
Inclusion criteria: Patients of both sexes (18-75 years) with hemodynamic diagnosis of PAH and severe vitamin D deficiency (25-OHvitD \<= 12 ng/ml) and without previous diagnosis of osteoporosis or osteomalacia.
Treatments: 1) Calcifediol Hydroferol® 0.266 mg once every 10 days for the first 12 weeks and once every two weeks for the following 12 weeks. 2) Placebo.
Main objective: A composite endpoint of clinical improvement without clinical worsening at week 24.
Expected outcome: Restoration of vitamin D status is an unexpensive measure, very easily implantable and that could improve the evolution of the disease as well as other aspects such as bone or immune health and that has few side effects.
Phase:
PHASE4
Details
Lead Sponsor:
Parc de Salut Mar
Collaborators:
Hospital Clinic of Barcelona Hospital Universitario de Gran Canaria Doctor Negrín Hospital Universitario Doctor Peset Hospital Universitario La Fe Hospital Universitario Marqués de Valdecilla Hospital Universitario Ramon y Cajal Hospital Vall d'Hebron Hospitales Universitarios Virgen del Rocío Universidad Complutense de Madrid